通过增强的采样模拟,发现针对G12D突变体的活性泛KRas抑制剂
1School of Biomedical Engineering, Guangdong Medical University, Dongguan 523808, China.
The journal of physical chemistry. B
|September 4, 2025
概括
研究人员发现了抑制KRas G12D突变的新型化合物SS-3091和SS-30125. 这些泛KRas抑制剂在治疗由Ras突变驱动的各种癌症方面具有前景.
科学领域:
- 癌症学
- 分子生物学
- 计算化学
背景情况:
- 拉斯蛋白是细胞信号通路的关键调节者.
- 在人类癌症中,Ras突变,特别是KRas G12D,很常见.
- RAS-RAF-MEK通路是癌症治疗的关键目标.
研究的目的:
- 调查KRas G12D突变的形状情况.
- 确定针对KRas G12D的新型抑制剂.
- 评估已识别的抑制剂对各种Ras突变的治疗潜力.
主要方法:
- KRas G12D的复制交换分子动力学 (REMD) 模拟.
- 基于特定KRas G12D形状的分子图书馆选.
- 抑制剂-蛋白质复合物的分子对接和分子动力学 (MD) 模拟.
- 对多种KRas突变的抗癌活性在体外验证.
主要成果:
- 与野生类型的KRas相比,KRas G12D具有不同的形状空间.
- 两个化合物SS-3091和SS-30125显示出显著的抑制作用.
- SS-3091和SS-30125通过结合它们的相互作用接口来破坏KRas-ARaf复合体的稳定.
- 这些化合物在KRas G12D,G12C,G12V和G12S突变中显示出有效的抗癌活性.
结论:
- SS-3091和SS-30125是KRas G12D和其他Ras突变的强有力的抑制剂.
- 这些化合物代表了广泛的KRas驱动癌症的有前途的治疗候选物.
- 这些发现突显了针对药物发现的特定KRas构造的潜力.
相关概念视频
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity: